Sarepta shares yo-yo in the red on another glimpse of stellar results for Duchenne MD gene therapy — what gives?
There’s just no telling what a stock will do — even when you stack the deck in your favor.
Tonight Sarepta $SRPT came out with a GREAT piece of news. Adding to the stellar, but very early glimpse of positive data for their gene therapy for Duchenne muscular dystrophy, the biotech updated their data with a set of new numbers that would appear to add to the overall glow of the program.
And then its stock took a dive, falling close to 10% in a matter of minutes after the delayed release hit the wires. Then it bounced back, only a few points in the red. What gives?
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.